Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Intra-Cellular Therapies, Inc. | d285960dex321.htm |
| EX-31.2 - EX-31.2 - Intra-Cellular Therapies, Inc. | d285960dex312.htm |
| EX-31.1 - EX-31.1 - Intra-Cellular Therapies, Inc. | d285960dex311.htm |
| EX-21.1 - EX-21.1 - Intra-Cellular Therapies, Inc. | d285960dex211.htm |
| EX-10.3 - EX-10.3 - Intra-Cellular Therapies, Inc. | d285960dex103.htm |
| 10-K - FORM 10-K - Intra-Cellular Therapies, Inc. | d285960d10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) Registration Statement (Form S-3 No. 333-213495) of Intra-Cellular Therapies, Inc.,
(2) Registration Statement (Form S-8 No. 333-205070) of Intra-Cellular Therapies, Inc. pertaining to the Intra-Cellular Therapies, Inc. Amended and Restated 2013 Equity Incentive Plan,
(3) Registration Statement (Post-Effective Amendment No. 3 to Form S-1 on Form S-3 No. 333-191238) of Intra-Cellular Therapies, Inc., and
(4) Registration Statement (Form S-8 No. 333-193310) of Intra-Cellular Therapies, Inc. pertaining to the ITI, Inc. 2003 Equity Incentive Plan, as amended, and the Intra-Cellular Therapies, Inc. Amended and Restated 2013 Equity Incentive Plan;
of our reports dated March 1, 2017, with respect to the consolidated financial statements of Intra-Cellular Therapies, Inc. and the effectiveness of internal control over financial reporting of Intra-Cellular Therapies, Inc. included in this Annual Report (Form 10-K) of Intra-Cellular Therapies, Inc. for the year ended December 31, 2016.
/s/ Ernst & Young LLP
Baltimore, MD
March 1, 2017